BNC105P, with the CAS number 945771-96-0, is a small molecule that has been investigated primarily for its potential use in cancer therapy. It functions as a vascular disrupting agent, targeting the tumor vasculature to inhibit blood supply to tumors, thereby inducing tumor cell death. The compound is characterized by its ability to selectively disrupt the blood vessels that supply nutrients and oxygen to tumors, which can enhance the efficacy of other anticancer treatments. BNC105P has shown promise in preclinical studies and early-phase clinical trials, demonstrating a favorable safety profile and the potential to improve outcomes in various cancer types. Its mechanism of action involves the destabilization of the endothelial cells lining the blood vessels, leading to increased tumor hypoxia and subsequent cell death. As research continues, BNC105P may contribute to the development of novel therapeutic strategies in oncology, particularly in combination with other treatments to overcome resistance and improve patient prognosis.

BNC105P

945771-96-0: BNC105P, with the CAS number 945771-96-0, is a small molecule that has been investigated primarily for its potential use in cancer therapy. It functions as a vascular disrupting agent, targeting the tumor vasculature to inhibit blood supply to tumors, thereby inducing tumor cell death. The compound is characterized by its ability to selectively disrupt the blood vessels that supply nutrients and oxygen to tumors, which can enhance the efficacy of other anticancer treatments. BNC105P has shown promise in preclinical studies and early-phase clinical trials, demonstrating a favorable safety profile and the potential to improve outcomes in various cancer types. Its mechanism of action involves the destabilization of the endothelial cells lining the blood vessels, leading to increased tumor hypoxia and subsequent cell death. As research continues, BNC105P may contribute to the development of novel therapeutic strategies in oncology, particularly in combination with other treatments to overcome resistance and improve patient prognosis.

<p>BNC105P is a monoclonal antibody that blocks the receptor for stem cell factor. It has shown to be effective in slowing tumor growth in xenograft tumors. BNC105P inhibits cancer by blocking the receptor molecule and inhibiting the production of growth factors, which are necessary for cell division. The mechanism of action of BNC105P is still being studied.</p>

<p>BNC105P, a prodrug VDA, converts to BNC105, blocks tubulin polymerization, disrupts tumor vessels, and evades P-glycoprotein resistance.</p>

CAS 945771-96-0

BNC105P

BNC105P

Ref: 3D-FB176471

BNC105P

Ref: TM-T68273